Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of GSK3862995B in bronchiectasis
jRCT2031250446Phase 2Recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of gsk3862995b in bronchiectasis (3 arms), sponsored by GSK. Primary endpoint: Annualized rate of exacerbations. Started Feb 2026; status: recruiting.
02
Drugs
gsk3862995b
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2031250446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250446.